NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to ...

Detailed price information for Cellectis S.A. ADR (CLLS-Q) from The Globe and Mail including charting and trades.

An update from Cellectis SA ( (CLLS)) is now available. On May 11, 2026, Cellectis reported first-quarter 2026 results and highlighted progress across its pipeline, including pivotal Phase 2 ...

More than a decade ago Sonia Vallabh, a lawyer, and her husband, an engineer, decided to retrain as molecular biologists. They had an urgent motivation. Dr Vallabh’s mother had died suddenly of a ...

Epigenome editing has undergone something of a renaissance in recent years, but scientists have been using basic gene-modulation tools for much longer. Two of the earliest were transcriptional ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...

The world watched on in awe as teams successfully administered a personalized gene therapy to infant KJ Muldoon ("Baby KJ"). This extraordinary achievement reignited public and scientific excitement ...

Epigenetics refer to DNA modifications that may affect phenotype but don’t alter the nucleotide sequence itself. Epigenetic changes can often be passed down generations, hence the Greek prefix “epi”, ...

Bulletin: ...FROST ADVISORY REMAINS IN EFFECT UNTIL 8 AM EDT TUESDAY... * WHAT...Temperatures as low as 33 will result in frost formation. * WHERE...A portion of ...